WeTrials
Recruiting

A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

What is this study?

This study is testing a combination of two targeted cancer drugs, MRX-2843 and osimertinib, for advanced non-small cell lung cancer. Researchers want to find the safest and most effective doses to help stop the tumor cells from growing.

Who can participate?

You might be able to join if you have advanced non-small cell lung cancer with specific EGFR gene changes, can swallow pills easily, and are generally well enough to go about your daily routine.

What will happen?

Participants will take the study medications by mouth while doctors closely monitor your health, check for side effects, and measure how the tumors respond to the treatment.

Where and when?

This study is currently recruiting participants and takes place in Atlanta, Georgia, in the United States.

Key Points
  • 1Tests a new drug combination for advanced lung cancer
  • 2Requires specific genetic changes in the cancer
  • 3Currently looking for participants in Atlanta, Georgia

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.